NCT00825981

Brief Summary

Patients undergoing elective coronary artery bypass graft surgery (CABG) are treated with platelet inhibitors to reduce myocardial infarction and mortality.However, this can increase perioperative bleeding. A retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective CABG since 5 years. The aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2009

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

January 16, 2009

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 21, 2009

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2010

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2010

Completed
Last Updated

July 23, 2010

Status Verified

July 1, 2010

Enrollment Period

1 year

First QC Date

January 16, 2009

Last Update Submit

July 22, 2010

Conditions

Coronary Disease

Study Arms (1)

coronary artery bypass graft

patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass

Other: screening coagulation abnormalities

Interventions

screening coagulation abnormalitiesOTHER

if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start

coronary artery bypass graft

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

coronary artery bypass graft

You may qualify if:

  • coronary artery bypass graft surgery with or without cardiopulmonary bypass

You may not qualify if:

  • emergency; redo cardiac surgery; combined cardiac surgery; patients with renal insufficiency; patients with acquired coagulation abnormalities

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cliniques Universitaires Saint Luc

Brussels, Brussels Capital, 1200, Belgium

Location

Related Publications (1)

  • Hertfelder HJ, Bos M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005;31(4):426-40. doi: 10.1055/s-2005-916678.

    PMID: 16149021BACKGROUND

MeSH Terms

Conditions

Coronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

January 16, 2009

First Posted

January 21, 2009

Study Start

January 1, 2009

Primary Completion

January 1, 2010

Study Completion

March 1, 2010

Last Updated

July 23, 2010

Record last verified: 2010-07

Locations

BE(1)